Differential effects of adjunctive methylphenidate and citalopram on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain

European Neuropsychopharmacology

Volumn 17, Issue 10, 2007, Pages 658-671

  Weikop, Pia ^a   Yoshitake, Takashi ^b   Kehr, Jan ^b  

^a NEUROSEARCH A S   (Denmark)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antidepressants; Augmentation therapy; Citalopram; Methylphenidate; Microdialysis

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DOPAMINE; METHYLPHENIDATE; NORADRENALIN; SEROTONIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DRUG MECHANISM; DRUG POTENTIATION; HIPPOCAMPUS; MALE; MICRODIALYSIS; MONOTHERAPY; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ANIMALS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BRAIN; CITALOPRAM; DOPAMINE; DRUG INTERACTIONS; EXTRACELLULAR FLUID; MALE; METHYLPHENIDATE; MICRODIALYSIS; MOTOR ACTIVITY; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 34548030683     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.02.014     Document Type: Article

References (91)

1. Adell A., and Artigas F. Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo microdialysis study. Naunyn Schmiedeberg's Arch. Pharmacol. 343 (1991) 237-244
2. Adell A., and Artigas F. The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci. Biobehav. Rev. 28 (2004) 415-431
3. Ago Y., Nakamura S., Baba A., and Matsuda T. Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex. Neuropsychopharmacology 30 (2005) 43-51
4. 1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedeberg's Arch. Pharmacol. 347 (1993) 353-362
5. Arborelius L., Nomikos G.G., Hacksell U., and Svensson T.H. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol. Scand. 148 (1993) 465-466
6. Artigas F., Perez V., and Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry 51 (1994) 248-251
7. 1A antagonists. Trends Neurosci. 19 (1996) 378-383
8. 1b-adrenergic receptors. J. Neurochem. 91 (2004) 318-326
9. Bader G.M., Hawley J.M., and Short D.D. Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report. J. Clin. Psychopharmacol. 18 (1998) 255-256
10. Björklund A., and Lindvall O. Dopamine-containing systems in the CNS. In: Björklund A., and Hökfelt T. (Eds). Handbook of Chemical Neuroanatomy. Classical transmitters in the CNS vol. 2 (1984), Elsevier, Amsterdam 55-122
11. Blier P., and de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 21 (1999) 91S-98S (Suppl)
12. Butcher S.P., Liptrot J., and Aburthnott G.W. Characterisation of methylphenidate and nomifensine induced dopamine release in rat striatum using in vivo brain microdialysis. Neurosci. Lett. 122 (1991) 245-248
13. Campbell A.D., and McBride W.J. Serotonin-3 receptor and ethanol-stimulated dopamine release in the nucleus accumbens. Pharmacol. Biochem. Behav. 51 (1996) 835-842
14. Castellanos F.X., Elia J., Kruesi M.J., Marsh W.L., Gulotta C.S., Potter W.Z., Ritchie G.F., Hamburger S.D., and Rapoport J.L. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacology 14 (1996) 125-137
15. Ceci A., Baschirotto A., and Borsini F. The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex. Neuropharmacology 33 (1994) 709-713
16. Challman T.D., and Lipsky J.J. Methylphenidate: its pharmacology and uses. Mayo Clin. Proc. 75 (2000) 711-721
17. 3 receptor activation in medial prefrontal cortex of freely moving rats. Synapse 10 (1992) 264-266
18. 2C receptors potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacology 29 (2004) 1782-1789
19. Denys D., Klompmakers A.A., and Westenberg H.G. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl) 176 (2004) 195-203
20. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci. 25 (2005) 10831-10843
21. Di Mascio M., Di Giovanni G., Di Matteo V., Prisco S., and Esposito E. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Brain Res. Bull. 46 (1998) 547-554
22. 2C receptors in the control of central dopamine function. Trends Pharmacol. Sci. 22 (2001) 229-232
23. Ferris R.M., Tang F.L., and Maxwell R.A. A comparison of the capacities of isomers of amphetamine, deoxypipradrol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta. J. Pharmacol. Exp. Ther. 181 (1972) 407-416
24. Freund T.F., Gulyas A.I., Acsady L., Gorcs T., and Toth K. Serotonergic control of the hippocampus via local inhibitory interneurons. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 8501-8505
25. Gerasimov M.R., Franceschi M., Volkow N.D., Gifford A., Gatley S.J., Marsteller D., Molina P.E., and Dewey S.L. Comparison between intraperitoneal and oral methylphenidate administration: a microdialysis and locomotor activity study. J. Pharmacol. Exp. Ther. 295 (2000) 51-57
26. 2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 38 (1999) 315-317
27. 2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J. Neurochem. 69 (1997) 2616-2619
28. Gobert A., Rivet J.M., Audinot V., Newman-Tancredi A., Cistarelli L., and Millan M.J. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto-and heteroreceptor-mediated control of release. Neuroscience 84 (1998) 413-429
29. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36 (2000) 205-221
30. Gwirtsman H.E., Szuba M.P., Toren L., and Feist M. The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate. Psychopharmacol. Bull. 30 (1994) 157-164
31. Herve D., Pickel V.M., Joh T.H., and Beaudet A. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res. 435 (1987) 71-83
32. Huff J.K., and Davies M.I. Microdialysis monitoring of methylphenidate in blood and brain correlated with changes in dopamine and rat activity. J. Pharm. Biomed. Anal. 29 (2002) 767-777
33. Hurd Y.L., and Ungersted U. In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur. J. Pharmacol. 166 (1989) 251-260
34. 1A receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J. Pharmacol. Exp. Ther. 291 (1999) 1227-1232
35. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76 (2001) 1521-1531
36. Iyer R.N., and Bradberry C.W. Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J. Pharmacol. Exp. Ther. 277 (1996) 40-47
37. Kehr J. Monitoring chemistry of brain microenvironment: biosensors, microdialysis and related techniques. Chapter 41. In: Windhorst U., and Johansson H. (Eds). Modern Techniques in Neuroscience Research (1999), Springer-Verlag, Heidelberg 1149-1198
38. 1A receptors are expressed by a subpopulation of cholinergic neurons in the rat medial septum and diagonal band of Broca - a double immunocytochemical study. Neuroscience 74 (1996) 143-154
39. Klint T., and Weikop P. Monoamine transporters as continuing targets for drug discovery in depression. Drug Discov. Today. Ther. Strat. 1 (2004) 111-116
40. Koch S., Perry K.W., and Bymaster F.P. Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 46 (2004) 232-242
41. Kuczenski R., and Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 68 (1997) 2032-2037
42. Kuczenski R., and Segal D.S. Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J. Pharmacol. Exp. Ther. 296 (2001) 876-883
43. 6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse 51 (2004) 158-164
44. Lam R.W., Hossie H., Solomons K., and Yatham L.N. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J. Clin. Psychiatry 65 (2004) 337-340
45. Lavretsky H., and Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am. J. Geriatr. Psychiatry 9 (2001) 298-303
46. Lavretsky H., Kim M.D., Kumar A., and Reynolds III C.F. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J. Clin. Psychiatry 64 (2003) 1410-1414
47. 1A receptors: WAY100, 635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse 30 (1998) 172-180
48. 2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 947 (2002) 157-165
49. Masand P.S., Anand V.S., and Tanquary J.F. Psychostimulant augmentation of second generation antidepressants: a case series. Depress Anxiety 7 (1998) 89-91
50. Millan M.J. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur. J. Pharmacol. 500 (2004) 371-384
51. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 110 (2006) 135-370
52. 2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity. J. Pharmacol. Exp. Ther. 282 (1997) 132-147
53. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37 (1998) 953-955
54. Millan M.J., Gobert A., Girardon S., and Dekeyne A. Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs. dopamine and noradrenaline. Eur. J. Pharmacol. 364 (1999) 147-150
55. Millan M.J., Lejeune F., and Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J. Psychopharmacol. 14 (2000) 114-138
56. Millan M.J., Gobert A., Lejeune F., Newman-Tancredi A., Rivet J.M., Auclair A., and Peglion J.L. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J. Pharmacol. Exp. Ther. 298 (2001) 565-580
57. 1A receptor activation. Brain Res. Bull. 63 (2004) 237-241
58. Niederhofer H. Therapy refractory depression: symptom improvement after antidepressant and methylphenidate combination therapy. Wien Med. Wochenschr. 152 (2002) 578-580
59. Ninan P.T., Hassman H.A., Glass S.J., and McManus F.C. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. J. Clin. Psychiatry 65 (2004) 414-420
60. 1B receptors in the ventral tegmental area modulate cocaine-induced increases in nucleus accumbens dopamine levels. J. Pharmacol. Exp. Ther. 311 (2004) 711-719
61. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Co-ordinates (1997), Academic Press, New York
62. Pickel V.M., Joh T.H., and Reis D.J. A serotonergic innervation of noradrenergic neurons in nucleus locus coeruleus: demonstration by immunocytochemical localization of the transmitter specific enzymes tyrosine and tryptophan hydroxylase. Brain Res. 131 (1977) 197-214
63. Prisco S., and Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br. J. Pharmacol. 116 (1995) 1923-1931
64. Prisco S., Pagannone S., and Esposito E. Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo. J. Pharmacol. Exp. Ther. 271 (1994) 83-90
65. Reith M.E., Li M.Y., and Yan Q.S. Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacology (Berl) 134 (1997) 309-317
66. Reynolds III C.F., Frank E., Perel J.M., Mazumdar S., Dew M.A., Begley A., Houck P.R., Hall M., Mulsant B., Shear M.K., Miller M.D., Cornes C., and Kupfer D.J. High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression. Am. J. Psychiatry 153 (1996) 1418-1422
67. Ritz M.C., Lamb R.J., Goldberg S.R., and Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237 (1987) 1219-1223
68. 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol. Psychiatry 48 (2000) 229-237
69. Roose S.P., Sackeim H.A., Krishnan K.R., Pollock B.G., Alexopoulos G., Lavretsky H., Katz I.R., Hakkarainen H., and Old-Old Depression Study Group. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am. J. Psychiatry 161 (2004) 2050-2059
70. Sacchetti G., Bernini M., Bianchetti A., Parini S., Invernizzi R.W., and Samanin R. Study on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain. Br. J. Pharmacol. 128 (1999) 1332-1338
71. 1A receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br. J. Pharmacol. 129 (2000) 1028-1034
72. Schwartz T.L., Azhar N., Cole K., Hopkins G., Nihalani N., Simionescu M., Husain J., and Jones N. An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. J. Clin. Psychiatry 65 (2004) 1223-1227
73. Shelton R.C., Tollefson G.D., Tohen M., Stahl S., Gannon K.S., Jacobs T.G., Buras W.R., Bymaster F.P., Zhang W., Spencer K.A., Feldman P.D., and Meltzer H.Y. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry 158 (2001) 131-134
74. Shelton R.C., Williamson D.J., Corya S.A., Sanger T.M., Van Campen L.E., Case M., Briggs S.D., and Tollefson G.D. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psychiatry 66 (2005) 1289-1297
75. Shelton Clauson A., Elliott E.S., Watson B.D., and Treacy J. Coadministration of phenelzine and methylphenidate for treatment-resistant depression. Ann. Pharmacother. 38 (2004) 508
76. Skolnick P., Popik P., Janowsky A., Beer B., and Lippa A.S. "Broad spectrum" antidepressants: is more better for the treatment of depression?. Life Sci. 73 (2003) 3175-3179
77. Solanto M.V. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav. Brain Res. 94 (1998) 127-152
78. 1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology 27 (1988) 707-715
79. Stoll A.L., Pillay S.S., Diamond L., Workum S.B., and Cole J.O. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J. Clin. Psychiatry 57 (1996) 72-76
80. Takahashi H., Yoshida K., Higuchi H., Shimizu T., Inoue T., and Koyama T. Addition of a dopamine agonist, cabergoline, to a serotonin-noradrenalin reuptake inhibitor, milnacipran as a therapeutic option in the treatment of refractory depression: two case reports. Clin. Neuropharmacol. 26 (2003) 230-232
81. Tanda G., Carboni E., Frau R., and Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?. Psychopharmacology (Berl) 115 (1994) 285-288
82. 1A receptors and independence from noradrenergic innervation. J. Neurochem. 93 (2005) 371-382
83. Volkow N.D., Ding Y.S., Fowler J.S., Wang G.J., Logan J., Gatley J.S., Dewey S., Ashby C., Liebermann J., Hitzemann R., et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch. Gen. Psychiatry 52 (1995) 456-463
84. Volkow N.D., Fowler J.S., Wang G.J., Ding Y.S., and Gatley S.J. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur. Neuropsychopharmacol. 12 (2002) 557-566
85. Weikop P., Egestad B., and Kehr J. Application of triple-probe microdialysis for fast pharmacokinetic/pharmacodynamic evaluation of dopamimetic activity of drug candidates in the rat brain. J. Neurosci. Methods 140 (2004) 59-65
86. 2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. J. Psychopharmacol. 18 (2004) 395-403
87. Woods S.K., and Meyer J.S. Exogenous tyrosine potentiates the methylphenidate-induced increase in extracellular dopamine in the nucleus accumbens: a microdialysis study. Brain Res. 560 (1991) 97-105
88. 2-adrenoceptors. Br. J. Pharmacol. 128 (1999) 659-666
89. Yamaguchi M., Yoshitake T., Fujino K., Kawano K., Kehr J., and Ishida J. Determination of norepinephrine in microdialysis samples by microbore column liquid chromatography with fluorescence detection following derivatization with benzylamine. Anal. Biochem. 270 (1999) 296-302
90. 1B receptors within the ventral tegmental area in regulation of mesolimbic dopaminergic neuronal activity via GABA mechanisms: a study with dual-probe microdialysis. Brain Res. 1021 (2004) 82-91
91. Zhang W., Perry K.W., Wong D.T., Potts B.D., Bao J., Tollefson G.D., and Bymaster F.P. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23 (2000) 250-262